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Economic evaluation in the form of cost-effectiveness analysis has become a popular
means to inform decisions in healthcare. With multi-regional clinical trials in a global
development program becoming a new venue for drug efficacy testing in recent decades,
questions in methods for cost-effectiveness analysis in the multi-regional clinical trials
setting also emerge. This paper addresses some challenges from variation across regions
in cost effectiveness analysis in multi-regional clinical trials. Several discussion points
are raised for further attention and a multi-regional clinical trial example is presented to
illustrate the implications in industrial application. A general message is delivered to call
for a depth discussion by all stakeholders to reach an agreement on a good practice in
cost-effectiveness analysis in the multi-regional clinical trials. Meanwhile, we recommend
an additional consideration of cost-effectiveness analysis results based on the clinical
evidence from a certain homogeneous population as sensitivity or scenario analysis upon
data availability.
Keywords: cost-effectiveness analysis, multi-regional clinical trials, ethnic factors, sensitivity analysis, clinical
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INTRODUCTION
Cost-effectiveness analysis (CEA) involves a comparison of two or more treatments to assess
differences in terms of the interventions’ costs relative to their effectiveness. One or more
new interventions are compared against the intervention currently being implemented. Cost-
effectiveness is, by nature, incremental (Weintraub and Cohen, 2009). Thus, the final results of
the CEA, accompanied by a proper uncertainty analysis, can be presented as an incremental
cost-effectiveness ratio (ICER) and net health benefit (NHB) or net monetary benefit (NMB).
Economic evaluation, in the form of cost-effectiveness analyses, has become a popular means
to inform decisions about healthcare priorities (George et al., 2001). It is particularly useful for
and applied to decision-makings in the drug market access activities, by comparing ICER to a
threshold value, above which an intervention is considered to be not cost effective. Organizations
including the National Institute for Health and Care Excellence (NICE) of UK (Birch and Gafni,
2004), Pharmaceutical Benefits Advisory Committee (PBAC) of Australia, and Canadian Agency
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for Drugs and Technology in Health (CADATH) of Canada
require economic evaluations before approving a new drug for
market or incorporating a drug into insurance plans (Hjelmgren
et al., 2001). When conducting economic evaluation analysis
about efficacy and safety outcomes, models are generally created
using the data from randomized control trials (RCTs) or they
are synthesized using data from meta-analyses. There are a
growing number of clinical trials that include data specifically
about resource utilization and outcomes for the purposes of
cost-effectiveness (Ramsey et al., 2015). However, RCTs do not
always provide a sufficient basis for economic evaluations used
to inform regulatory and reimbursement decisions (Petrou and
Gray, 2011). Usually, the time necessary to perform a cost-
effectiveness analysis extends beyond the data collected during
RCTs, thus requiring outcome modeling as opposed to direct
measurement (Weintraub and Cohen, 2009). To be complete,
CEA must consider short-term costs and benefits (e.g., as are
observed during an actual RCT) as well as assess longer-term
outcomes (Luce et al., 1996). To accomplish this task, decision
analysis methodology such as Markov model is often needed to
link short—and long-term outcomes.
Final cost-effectiveness results for drugs under appraisal
or those that are newly licensed, are often generated by
incorporating health outcomes from phase II/III clinical
trials with unit costs and healthcare resource utilization of
treatment within a specific country. This approach would be
straightforward if efficacy/effectiveness data were generated from
RCT(s) conducted in a single country where the economic
evaluation was conducted. However, multi-regional clinical trials
(MRCT) in global development programs have gained popularity
in recent decades (Ho and Chow, 1998), especially after the
release of the International Council for Harmonisation of
Technical Requirements for Pharmaceuticals for Human Use
(ICH) Guidance E5 addressing ethnic factors for acceptability
of foreign data in the drug registration evaluation (Guideline,
2016a). The rising prevalence of MRCT has introduced new
questions about CEA methods, especially surrounding data
related to clinical evidence. The economic evidence hereafter
refers to resource utilization, unit cost, and their product or a
macro costing result.
This paper aims to address common issues encountered
when performing cost-effectiveness evaluations of MRCTs with
potential heterogeneity and variability across regions. Several
discussion points are raised to increase attention about these
issues and charge the field to further explore this methodology.
HETEROGENEITY IN CEA
In general, CEA of a treatment should be analyzed at the
country level due to differences in demographics, healthcare
systems, and cost structures. Health Technology Assessment
(HTA) countries like Australia, Canada, and the UK have
established guidelines related to health economic evaluations.
Further, an increasing number of other countries have developed
principles and recommendations to be used for health economic
evaluations (Hjelmgren et al., 2001).
A recent review (Barbieri et al., 2010) documented that the
recommendations included within existing guidelines regarding
the transferability/variability of clinical and economic data are
quite diverse. Almost all guidelines unanimously considered
baseline risk and unit costs to be of low transferability, while
treatment effects were classified as highly transferable. However,
some guidelines recognized the potential differences in the
clinical parameters from one country to another, and these
country-specific differences can lead to differences in cost-
effectiveness estimates.
Theoretically, clinical variability can be attributed to diverse
clinical practice patterns or inherent heterogeneity in the
patient population within different geographical areas or
settings (Canadian Coordinating Office for Health Technology
Assessment, 1997). Within a country, the government and other
healthcare payers have recognized that a refined reimbursement
approach can be achieved to prioritize the patients’ needs by
gaining a better understanding of the heterogeneity among
eligible patients in terms of effectiveness and cost (Coyle et al.,
2003). By extension, when a cost-effectiveness analysis based on
an MRCT is needed, it may be more appropriate to conduct
the analysis within a relative homogeneous group to control the
variability in clinical and economic evidences. However, many
clinical trials do not have enough subjects in each country/region
for clinical effect estimations, and such underpowered subgroup
analyses could lead to broader confidence intervals and more
uncertainty about CEA results.
To account for variability across different countries/regions
in MRCT when conducing CEA, the current popular practice
is to use local costs and/or baseline risk, which are associated
with high variability. When considering clinical evidences such
as treatment effects, overall estimations are often used despite
their use presenting challenges in certain circumstances. Using
overall estimates may cause confusion by assuming the relative
clinical effectiveness of the intervention does not differ across
populations. Therefore, we agree with Reed that if the number
of enrolled patients is large or there is strong evidence showing
the existence of high variability, country—or region-specific
clinical evidence, e.g., event rates estimation and treatment effects
in response to baseline risks and other local evidences, may
be appropriate (Reed, 2012). But, if large patient numbers are
not available, modeling CEA with local economic evidences
combined with overall clinical evidences would be a plausible
trade-off. However, it is still worthy to explore the CEA
results based on country—or region specific treatment effects
as sensitivity or scenario analyses (e.g., as a reference for local
decision makers).
CONSISTENCY WITHIN MRCT
Multi-Regional Clinical Trials (MRCT) as a methodology have
potential to simultaneously register innovative drugs worldwide.
In recent years, efforts have been made for the planning
and design of MRCTs to increase the acceptability of MRCTs
in global regulatory submissions. ICH is currently drafting
the new guidance document E17 to guide the sponsors to
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address the issues surrounding MRCT (Guideline, 2016b).
Well-reasoned and prospectively planned analysis to assess the
impact of intrinsic and extrinsic factors on treatment effects
are encouraged for the establishment of a good foundation
for evaluating the consistency of region specific treatment
effects.
With multiple regions involved, intrinsic and extrinsic factors
may vary across regions due to ethnicity, culture, patient
population, and local medical practice (Guideline, 2016a). Given
that the early clinical evidence generally concludes the lack of
significant ethnicity-related drug sensitivity and supports regions
joining MRCTs, we may not expect these differences to have
a major impact on clinical outcomes and treatment effects.
Nevertheless, such differences may in fact influence outcomes
and effects but not be considered when interpreting the most
beneficial treatment for patients.
While the overall treatment effect is addressed and estimated
in MRCT, the main challenge is associated with estimating effects
within individual regions/countries. This challenge can make
it difficult to discern whether signals of regional differences
reflect a true interaction or whether the signal might be
largely due to statistical “noise” or a chance finding. The
subpopulation differences may not be examined in conventional
designs using hypothesis testing-based approaches, which rely
on the assumption of homogeneity. Conversely, exaggerated
signals of differences, which are legitimate concerns if they
truly exist, can be expected to arise frequently and might
be prone to over-interpretation. Regional differences can be
attributed to intrinsic/extrinsic factors (e.g., sociodemographic,
medical history, disease severity), and the varying distributions
of these factors within countries/regions. While these treatment
effects may differ across subpopulations, it is hoped that the
variance falls within a fairly narrow range and reasonable
degree.
Nevertheless, investigations about such factors are
helpful to understand the magnitude of differences to guide
recommendations for therapy utilization in clinical practices and
assess the associated impact of such therapies on the healthcare
costs. Because there is often large variability in data sources with
relatively small patient sizes from individual regions/countries,
it becomes difficult to draw definitive conclusions solely
based on the effect estimation from a particular region/
country.
To address this issue, countries can be combined into
different definitions of a factor region, and region effects can
be compared in different manners. Further, more advanced
statistical techniques can be used to identify other similar
subpopulations from the overall trial population, which match
with the regional subpopulation on key characteristics (Dehejia
andWahba, 2002; Austin, 2014). For instance, recently developed
statistical methodologies have suggested that the Bayesian
shrinkage estimator can be used for the regional effect estimation
based on actual regional results borrowed from other regions
(Quan et al., 2013). It considers the treatment effort as a random
effort and estimates the mean effect and variance in the region
based on the shrinkage.
A TRIAL EXAMPLE
Dabigatran is an oral direct thrombin inhibitor (DTI) that was
approved in recent years for stroke and systemic embolism
(SE) prevention among patients with atrial fibrillation (AF).
Dabigatran was compared with warfarin in the RE-LY
(Randomized Evaluation of Long-Term Anticoagulation
Therapy) trial, which was a randomized study comparing two
different doses of Dabigatran (i.e., 150 and 110mg twice a day)
with warfarin (Connolly et al., 2009). In total, 18113 patients
from 44 countries were included in the trial. After a median
2-year follow-up, the RE-LY trial showed that the time to first
stroke or SE (i.e., primary outcome) was significantly better
with Dabigatran 150mg BID than warfarin. This finding was
associated with a mean therapeutic time in range of 64.4%
(median 67%). Dabigatran 110mg BID was non-inferior for
stroke/SE prevention. Dabigatran 150mg BID had similar rates
of major bleeds, while fewer major bleeds were observed with the
Dabigatran 110mg bid dose (Table 1; Connolly et al., 2009, 2010,
2014).
To assess the cost-effectiveness of Dabigatran, models were
developed to quantify comparisons with current care for
stroke prevention among patients with AF. Patients with AF
were followed for their remaining lifetime using model-based
approaches (e.g., Markov model). Treatment patterns and costs
were reflective of each country’s healthcare system. Risk of
clinical events for patients on warfarin and Dabigatran were
based on observed event rates in the RE-LY trial.
TABLE 1 | Main outcome in the RE-LY Trial.
Variable Dabigatran 110mg Dabigatran 150mg Warfarin Dabigatran 110mg vs. Warfarin Dabigatran 150mg vs. Warfarin
(N = 6015) (N = 6076) (N = 6022)
Rate/100 Rate/100 Rate/100 Relative Risk (95% CI) P-value Relative Risk (95% CI) P-value
person-yr person-yr person-yr
Stroke or SE 1.54 1.12 1.72 0.89 (0.73–1.09) 0.27 0.65 (0.52–0.81) <0.001
Major bleeding 2.92 3.40 3.61 0.80 (0.70–0.93) 0.003 0.94 (0.82–1.08) 0.41
Myocardial infarction 0.82 0.81 0.64 1.29 (0.96–1.75) 0.09 1.27 (0.94–1.71) 0.12
Gastrointestinal
major bleeding
1.15 1.56 1.07 1.08 (0.85–1.38) 0.52 1.48 (1.18–1.85) 0.001
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However, in some cases, the events rates in different
country/region subgroups might be inconsistent with the overall
population (for reasons previously described). For instance, the
incidence of intracerebral hemorrhage among Asian patients was
higher relative to patients of other ethnic origins (Figure 1). The
incidence of intracerebral hemorrhage among East and Southeast
Asian patients (51.8 per 100 000 person-years, 95% CI 38.8–69.3)
was over twice the incidence for Caucasian patients (24.2, 95% CI
20.9–28.0, reference group) (van Asch et al., 2010). Furthermore,
evidence shows that patients of Asian ethnicity are also at a
greater risk of hemorrhage while receiving vitamin K antagonist
therapy (Shen et al., 2007).
FIGURE 1 | Intracerebral hemorrhage incidence ratios in ethnic
groups. White ethnic origin was taken as reference. Circles are means and
bars are 95% CI. Reprinted from van Asch et al. (2010), Copyright (2010), with
permission from Elsevier
Another outcome of interest from the RE-LY trail was time
in therapeutic range (TTR), which is a commonly used measure
of the adequacy of international normalized ratio (INR) control
in studies with a warfarin arm. Increasing levels of site TTR
are associated with reduced rates of thrombotic events among
patients with AF treated with warfarin. But the warfarin control
was not balanced by region. In general, TTR was higher in
Western Europe and North America and lower in some locations
in the Asia-Pacific basin (Figure 2; Wallentin et al., 2010). This
variability of TTR will change the hazard ratio in warfarin
controlled trials of novel anticoagulants.
There were 2782 patients (15%) from 10 Asian countries in
the RE-LY trial. TTR was lower among Asian patients (mean,
54.5%) relative to non-Asian patients (66.2%), with less time
above (10.1% in Asian vs. 14.0% in non-Asian) and more time
below the therapeutic range (35.4 vs. 19.8%). As further noticed
in sub-group analyses, although Asian patients on warfarin
had considerably more time below therapeutic range and were
younger, a trend for more bleeding among Asian patients was
observed when compared to non-Asian patients. Meanwhile,
Dabigatran reduced the risk of bleeding outcomes more among
Asians than in non-Asians. There was a significant interaction
between treatment and region (Asian vs. non-Asian). The effects
of Dabigatran against stroke and SE were similar among Asian
and non-Asian patients for both doses of Dabigatran when
compared with warfarin (Table 2; Hori et al., 2013).
From the results of the RE-LY trial and its Asian subgroup
analysis, the efficacy of Dabigatran on stroke/SE was consistent
between Asian and non-Asians; however, the reductions in
major and total bleeding were greater with Dabigatran compared
to warfarin among Asian patients. The occurrence of MI in
Asian patients was also lower compared with that of non-Asian
patients. The emerging evidence suggests that if we use the
observed events rates from the RE-LY Asian sub-group, together
with the typical economic evidence from Asian countries’
healthcare systems, a more suitable CEA would be possible for
local decision-makers’ reference.
FIGURE 2 | Country distribution of mean time in therapeutic range in the RE-LY trial. Reprinted from Wallentin et al. (2010), Copyright (2010), with permission
from Elsevier.
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TABLE 2 | Main outcomes with Dabigatran vs. Warfarin in Asians in RE-LY trial.
Dabigatran 110mg
(N = 923)
Dabigatran 150mg
(N = 933)
Warfarin
(N = 926)
Dabigatran 110mg
vs. Warfarin
Dabigatran 150mg
vs. Warfarin
%/y %/y %/y HR (95% CI) HR (95% CI)
Stroke or SE 2.50 1.39 3.06 0.81 (0.54–1.21) 0.45 (0.28–0.72)
Major bleeding 2.22 2.17 3.82 0.57 (0.39–0.85) 0.57 (0.38–0.84)
Myocardial infarction 0.51 0.50 0.58 0.88 (0.36–2.17) 0.87 (0.35–2.13)
Gastrointestinal major bleeding 1.15 0.96 1.41 0.82 (0.45–1.49) 0.69 (0.37–1.27)
CONCLUDING REMARKS
The frequency of using MRCT will continue to increase
despite the difficulties associated with previously published
cost-effectiveness studies. One challenge is associated with
the quality of treatment effects data, which is crucial to
CEA. Variability is concerned with situations where input
parameters may vary systematically between recipients or
locations, and thus such variance should be considered and
adjusted for in MRCT. Though similar topics have been
raised in terms of heterogeneity, variability, and transferability
in economic evaluations using MRCT (Willke et al., 1998;
Reed et al., 2005; Drummond et al., 2009), such reports
have not clearly stated that the CEA methods associated
with MRCT varied between studies. In this context, we
suggest this issue be further discussed in-depth by stakeholders
in the scientific community to reach an agreement about
recommended best practices. Until then, especially given
increasing demands region/country-specific results to guide
local healthcare decisions, we recommend that CEA include
sensitivity or scenario analyses among certain homogeneous
subpopulations (as upon data availability) to improve clinical
decision making for diverse patients.
AUTHOR CONTRIBUTIONS
All authors contributed extensively to the work presented in this
paper including substantial contribution to the design/concept
presented, analysis, and interpretation. All authors have been
involved in crafting and editing drafts, have approved the final
submitted version, and agree to be accountable for all aspects of
the work.
FUNDING
YL research is supported by the Fundamental Research Funds for
the Central Universities from the Ministry of Education of the
People’s Republic of China, and the Research Funds (15XNI011)
of Renmin University of China.
REFERENCES
Austin, P. C. (2014). The use of propensity score methods with survival
or time-to-event outcomes: reporting measures of effect similar to those
used in randomized experiments. Stat. Med. 33, 1242–1258. doi: 10.1002/
sim.5984
Barbieri, M., Drummond, M., Rutten, F., Cook, J., Glick, H. A., Lis, J.,
et al. (2010). What do international pharmacoeconomic guidelines say about
economic data transferability?ValueHealth 13, 1028–1037. doi: 10.1111/j.1524-
4733.2010.00771.x
Birch, S., and Gafni, A. (2004). The ‘NICE’ approach to technology assessment:
an economics perspective. Health Care Manag. Sci. 7, 35–41. doi:
10.1023/B:HCMS.0000005396.69890.48
Canadian Coordinating Office for Health Technology Assessment (1997).
Guidelines for Economic Evaluation of Pharmaceuticals: Canada. 2nd Edn.
Ottawa, ON: Canadian Coordinating Office for Health Technology Assessment
(CCOHTA).
Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh,
A., et al. (2009). Dabigatran versus warfarin in patients with atrial fibrillation.
N. Engl. J. Med. 361, 1139–1151. doi: 10.1056/NEJMoa0905561
Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Reilly, P. A., and Wallentin, L. (2010).
Newly identified events in the RE-LY trial.N. Engl. J. Med. 363, 1875–1876. doi:
10.1056/NEJMc1007378
Connolly, S. J., Wallentin, L., and Yusuf, S. (2014). Additional events in
the RE-LY trial. N. Engl. J. Med. 371, 1464–1465. doi: 10.1056/NEJMc14
07908
Coyle, D., Buxton, M. J., and O’Brien, B. J. (2003). Stratified cost-effectiveness
analysis: a framework for establishing efficient limited use criteria.Health Econ.
12, 421–427. doi: 10.1002/hec.788
Dehejia, R. H., and Wahba, S. (2002). Propensity score-matching methods for
nonexperimental causal studies. Rev. Econ. Stat. 84, 151–161. doi: 10.1162/
003465302317331982
Drummond, M., Barbieri, M., Cook, J., Glick, H. A., Lis, J., Malik, F., et al.
(2009). Transferability of economic evaluations across jurisdictions: ISPOR
good research practices task force report. Value Health 12, 409–418. doi:
10.1111/j.1524-4733.2008.00489.x
George, B., Harris, A., and Mitchell, A. (2001). Cost-effectiveness analysis and
the consistency of decision making. Pharmacoeconomics 19, 1103–1109. doi:
10.2165/00019053-200119110-00004
Guideline, I. H. T. (2016a). Ethnic Factors in the Acceptability of Foreign Clinical
Data E5 (R1). Available online at: http://www.ich.org/fileadmin/Public_Web_
Site/ICH_Products/Guidelines/Efficacy/E5_R1/Step4/E5_R1__Guideline.pdf
(Accessed August 30, 1998).
Guideline, I. H. T. (2016b). General Principle on Planning/Designing Multi-
Regional Clinical Trials E17. Available online at: http://www.ich.org/fileadmin/
Public_Web_Site/ICH_Products/Guidelines/Efficacy/E17/E17_Step2.pdf
(Accessed September 5, 2016).
Hjelmgren, J., Berggren, F., and Andersson, F. (2001). Health economic
guidelines—similarities, differences and some implications. Value Health 4,
225–250. doi: 10.1046/j.1524-4733.2001.43040.x
Ho, H.-T., and Chow, S.-C. (1998). Design and analysis of multinational clinical
trials. Drug Inf. J. 32 (1 Suppl.), 1309S–1316S.
Frontiers in Pharmacology | www.frontiersin.org 5 October 2016 | Volume 7 | Article 371
Chu et al. Cost Effectiveness Analysis in MRCT
Hori, M., Connolly, S. J., Zhu, J., Liu, L. S., Lau, C.-P., Pais, P., et al. (2013).
Dabigatran versus warfarin effects on ischemic and hemorrhagic strokes and
bleeding in asians and non-asians with atrial fibrillation. Stroke 44, 1891–1896.
doi: 10.1161/STROKEAHA.113.000990
Luce, B. R., Manning, W. G., Siegel, J., and Lipscomb, J. (1996). “Estimating
costs in cost-effectiveness analysis,” in Cost-Effectiveness in Health
and Medicine, Vol. 3 (New York, NY: Oxford University Press),
176–213.
Petrou, S., and Gray, A. (2011). Economic evaluation using decision analytical
modelling: design, conduct, analysis, and reporting. BMJ 342:d1766. doi:
10.1136/bmj.d1766
Quan, H., Li, M., Shih, W. J., Ouyang, S. P., Chen, J., Zhang, J., et al. (2013).
Empirical shrinkage estimator for consistency assessment of treatment effects
in multi-regional clinical trials. Stat. Med. 32, 1691–1706. doi: 10.1002/
sim.5543
Ramsey, S. D., Willke, R. J., Glick, H., Reed, S. D., Augustovski, F., Jonsson, B.,
et al. (2015). Cost-effectiveness analysis alongside clinical trials II—an ISPOR
Good Research Practices Task Force report. Value Health 18, 161–172. doi:
10.1016/j.jval.2015.02.001
Reed, S. D. (2012). How country-specific should a country-specific cost-
effectiveness analysis be? Eur. Heart J. doi: 10.1093/eurheartj/ehs204.
Available online at: http://eurheartj.oxfordjournals.org/content/early/2012/07/
18/eurheartj.ehs204.short#ref-list-1
Reed, S. D., Anstrom, K. J., Bakhai, A., Briggs, A. H., Califf, R. M., Cohen, D.
J., et al. (2005). Conducting economic evaluations alongside multinational
clinical trials: toward a research consensus. Am. Heart J. 149, 434–443. doi:
10.1016/j.ahj.2004.11.001
Shen, A. Y.-J., Yao, J. F., Brar, S. S., Jorgensen, M. B., and Chen, W. (2007).
Racial/ethnic differences in the risk of intracranial hemorrhage among
patients with atrial fibrillation. J. Am. Coll. Cardiol. 50, 309–315. doi:
10.1016/j.jacc.2007.01.098
van Asch, C. J., Luitse, M. J., Rinkel, G. J., van der Tweel, I., Algra, A., and Klijn,
C. J. (2010). Incidence, case fatality, and functional outcome of intracerebral
haemorrhage over time, according to age, sex, and ethnic origin: a systematic
review and meta-analysis. Lancet Neurol. 9, 167–176. doi: 10.1016/S1474-
4422(09)70340-0
Wallentin, L., Yusuf, S., Ezekowitz, M. D., Alings, M., Flather, M., Franzosi, M.
G., et al. (2010). Efficacy and safety of dabigatran compared with warfarin at
different levels of international normalised ratio control for stroke prevention
in atrial fibrillation: an analysis of the RE-LY trial. Lancet 376, 975–983. doi:
10.1016/S0140-6736(10)61194-4
Weintraub,W. S., and Cohen, D. J., (2009). The limits of cost-effectiveness analysis.
Cir. Cardiovasc. Qual. Outcomes 2, 55–58. doi: 10.1161/CIRCOUTCOMES.108.
812321
Willke, R. J., Glick, H. A., Polsky, D., and Schulman, K. (1998). Estimating country-
specific cost-effectiveness from multinational clinical trials. Health Econ. 7,
481–493.
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2016 Chu, Dai, Qi, Smith, Huang, Li and Shen. This is an open-access
article distributed under the terms of the Creative Commons Attribution License (CC
BY). The use, distribution or reproduction in other forums is permitted, provided the
original author(s) or licensor are credited and that the original publication in this
journal is cited, in accordance with accepted academic practice. No use, distribution
or reproduction is permitted which does not comply with these terms.
Frontiers in Pharmacology | www.frontiersin.org 6 October 2016 | Volume 7 | Article 371
